Tag: trial

Experts Reveal 2025 Dog Gut Health Findings, Ingredient Transparency Push, and the Rise of Targeted Canine Probiotics

NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDAQ:NEOG), Alto Neuroscience, Inc. (NYSE:ANRO), RxSight, Inc. (NASDAQ:RXST), and Replimune Group, Inc. (NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648

London, United Kingdom, Aug. 02, 2025 (GLOBE NEWSWIRE) -- MGPD Finance Limited, doing business as HashJ, today announced the official launch of its short-term contracts dedicated to Shiba Inu Coin (SHIB), one of the most community-driven digital assets in the market. The new offering allows everyday users to engage with SHIB-linked reward plans designed for shorter durations and predictable outcomes—particularly as SHIB’s utility and adoption continue to expand globally.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) or PetCo (WOOF) To Contact Him Directly To Discuss Their Options

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025 in the securities class action first filed by the Firm.

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sable Offshore Corp. (NYSE: SOC): (1) between May 19, 2025 and June 3, 2025, both dates inclusive (the “Class Period”); and/or (2) pursuant and/or traceable to Sable’s May 21, 2025 secondary public offering (the “SPO”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 26, 2025.

London, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- MGPD Finance Limited, doing business as HashJ, today announced the official release of a new short-term participation contract focused on Bitcoin (BTC), designed for users navigating a market at a technical crossroads. The launch follows a period of directional indecision in the BTC market, as traders assess whether recent price action marks a consolidation phase or the early stage of a sustained move.

PLEASE CLICK HERE TO SUBMIT YOUR CONTACT INFORMATION

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio’s recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the “Board”) and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units (“RSUs”) for 153,505 shares of common stock (together, the “Inducement Awards”). The Inducement Awards were granted as inducements material to Dr. Yarema entering into employment with ImageneBio in accordance with Nasdaq Listing Rule 5635(c)(4).